HHS’ Azar Departing To Explore Private Sector Opportunities
This article was originally published in The Pink Sheet Daily
Executive Summary
Deputy Sectary to leave after five and a half years with department; no successor announced.
You may also be interested in...
Congress Will Look To “Hesitant” FDA To Regulate Biosimilars – Former HHS Deputy
Follow-on biologics, and their eventual road to approval, were weighty discussion topics on the opening day of the BIO CEO conference.
Congress Will Look To “Hesitant” FDA To Regulate Biosimilars – Former HHS Deputy
Follow-on biologics, and their eventual road to approval, were weighty discussion topics on the opening day of the BIO CEO conference.
Personalized Medicine To Be HHS Focus In Administration’s Final Thousand Days, Leavitt Says
HHS Secretary says “reinventing” FDA’s regulatory process and providing new financing mechanisms will be essential to bring about personalized therapies.